BIOMAT Database Logo BIOMAT Database Logo

Antagonist binding profiles of five cloned human muscarinic receptor subtypes. 1991

F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Laboratory of Molecular Biology, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20892.

A variety of muscarinic antagonists are currently used as tools to pharmacologically subclassify muscarinic receptors into M1, M2 and M3 subtypes. In the present study, we have determined the affinity profiles of several of these antagonists at five cloned human muscarinic receptors (m1-m5) stably expressed in Chinese hamster ovary cells (CHO-K1). At all five receptors, the (R)-enantiomers of trihexyphenidyl and hexbutinol displayed considerably higher affinities (up to 525-fold) than their corresponding (S)-isomers. The stereoselectivity ratios [inhibition constant(S)/inhibition constant(R)] for both pairs of enantiomers were lowest at m2 receptors, suggesting that less stringent configurational demands are made by this receptor subtype. The "M1-selective" antagonist (R)-trihexyphenidyl displayed high affinities for m1 and m4 receptors. The "M2-selective" antagonists himbacine, (+-)-5,11-dihydro-11- ([(2-[(dipropylamino)methyl]-1- piperidinyl)ethyl)amino]carbonyl)-6H-pyrido(2,3-b)(1,4)benzodiazepine-6- one (AF-DX 384), 11-[4-[4-(diethylamino)butyl]-1-piperidinyl)acetyl)-5,11- dihydro-6H-pyrido(2,3-b) (1,4)benzodiazepine-6-one (AQ-RA 741) and (+)-(11-[2-[(diethylamino) methyl]-1-piperidinyl)acetyl)-5,11-di-hydro-6H-pyrido(2,3-b)(1,4) benzodiazepine-6-one [AF-DX 250; the (+)-enantiomer of AF-DX 116] exhibited high affinities for m2 and m4, intermediate affinities for m1 and m3 and low affinities for m5 receptors. This selectivity profile was most prominent for AQ-RA 741, which displayed 195- and 129-fold higher affinities for m2 and m4 receptors than for m5 receptors.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D010276 Parasympatholytics Agents that inhibit the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the MUSCARINIC ANTAGONISTS. Antispasmodic,Antispasmodic Agent,Antispasmodic Drug,Antispasmodics,Parasympathetic-Blocking Agent,Parasympathetic-Blocking Agents,Parasympatholytic,Parasympatholytic Agent,Parasympatholytic Drug,Spasmolytic,Spasmolytics,Antispasmodic Agents,Antispasmodic Drugs,Antispasmodic Effect,Antispasmodic Effects,Parasympatholytic Agents,Parasympatholytic Drugs,Parasympatholytic Effect,Parasympatholytic Effects,Agent, Antispasmodic,Agent, Parasympathetic-Blocking,Agent, Parasympatholytic,Agents, Antispasmodic,Agents, Parasympathetic-Blocking,Agents, Parasympatholytic,Drug, Antispasmodic,Drug, Parasympatholytic,Drugs, Antispasmodic,Drugs, Parasympatholytic,Effect, Antispasmodic,Effect, Parasympatholytic,Effects, Antispasmodic,Effects, Parasympatholytic,Parasympathetic Blocking Agent,Parasympathetic Blocking Agents
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006224 Cricetinae A subfamily in the family MURIDAE, comprising the hamsters. Four of the more common genera are Cricetus, CRICETULUS; MESOCRICETUS; and PHODOPUS. Cricetus,Hamsters,Hamster
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012602 Scopolamine Derivatives Analogs or derivatives of scopolamine. Scopolamines,Derivatives, Scopolamine
D014162 Transfection The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES. Transfections
D019832 N-Methylscopolamine A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors. DD-234,Hyoscine Methiodide,Hyoscine Methobromide,Methscopolamine,Methylscopolamine Nitrate,Methylscopolammonium Methylsulfate,N-Methylscine Methylsulfate,N-Methylscopolamine Bromide,N-Methylscopolamine Iodide,N-Methylscopolamine Methylchloride,N-Methylscopolamine Methylsulfate,N-Methylscopolamine Nitrate,Scopolamine Methylbromide,Skopyl,Ulix,Bromide, N-Methylscopolamine,DD 234,DD234,Iodide, N-Methylscopolamine,Methiodide, Hyoscine,Methobromide, Hyoscine,Methylbromide, Scopolamine,Methylchloride, N-Methylscopolamine,Methylsulfate, Methylscopolammonium,Methylsulfate, N-Methylscine,Methylsulfate, N-Methylscopolamine,N Methylscine Methylsulfate,N Methylscopolamine,N Methylscopolamine Bromide,N Methylscopolamine Iodide,N Methylscopolamine Methylchloride,N Methylscopolamine Methylsulfate,N Methylscopolamine Nitrate,Nitrate, Methylscopolamine,Nitrate, N-Methylscopolamine

Related Publications

F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Radioligand binding studies. Pharmacological profiles of cloned Y-receptor subtypes.
January 2000, Methods in molecular biology (Clifton, N.J.),
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Antagonist binding properties of five cloned muscarinic receptors expressed in CHO-K1 cells.
April 1989, Molecular pharmacology,
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Synthesis and muscarinic receptor binding profiles of antagonist benzotriazole derivatives.
July 1993, Farmaco (Societa chimica italiana : 1989),
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Affinity profiles of various muscarinic antagonists for cloned human muscarinic acetylcholine receptor (mAChR) subtypes and mAChRs in rat heart and submandibular gland.
January 1999, Life sciences,
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes.
October 1991, Biochemical pharmacology,
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells.
March 1999, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Binding profiles of a series of 2-arylpropionic acid esters on cloned human muscarinic receptor subtypes (m1-m5) and their relationship to nootropic activity.
June 1999, Arzneimittel-Forschung,
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Pharmacological profiles of cloned mammalian P2Y-receptor subtypes.
June 2006, Pharmacology & therapeutics,
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Characterization of the binding of SCH 39166 to the five cloned dopamine receptor subtypes.
November 1994, Pharmacology, biochemistry, and behavior,
F Dörje, and J Wess, and G Lambrecht, and R Tacke, and E Mutschler, and M R Brann
Human prostate muscarinic receptor subtypes.
August 1995, The Journal of pharmacology and experimental therapeutics,
Copied contents to your clipboard!